

- Thank you moderator,
- Norway's intervention is on item 21.1 and the decision under this agenda point.
- Norway thanks Brazil and others for presenting the decision to prolong the GSPA from 2022 to 2030. We would request to be **added to the list of co-sponsors.**
- The GSPA is important because it contains elements needed to promote innovation, build capacity, improve access, and mobilize resources for health products.
- In our role as ACT-A Facilitation Council co-chair together with South Africa, we see a continued need to focus on these issues to ensure equitable access. This will also be an important part of the upcoming discussions on a new pandemic instrument.
- Norway has together with WHO EURO established **The Oslo Medicines Initiative** which facilitates a dialogue between the public and private sector, between countries, industry, patient organizations, professional organizations, and other stakeholders, to discuss and

reach consensus on how to improve access to effective, novel high-priced medicines.

- This dialogue and collaboration will explore how more sustainable health systems and a more sustainable pharmaceutical industry can be envisaged – in favor of patients. In this regard, transparency, solidarity, and sustainability are the three themes which underpin this initiative.
- Norway will host a **high-level meeting in Oslo this June** to discuss possible solutions for affordable medicines, more transparency and a more balanced relationship between the industry and national authorities.
- Thank you for your attention.